eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients Horn, L., Wu, Y., Reck, M., Wakelee, H. A., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Mok, T. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.TPS9115

View details for Web of Science ID 000442916008019